pharma_banner.gif
Home Animation
  • Home
  • Careers
  • Pharmaceutical Products
  • Imaging Products
  • Active Pharmaceutical Ingredients
  • Investors
  • Contact Us
  • Important Product Safety Information

    Optimark™

    Important Safety Alert regarding Coeur, Inc. disposable 125 mL syringe used in Optivantage™ DH Contrast Media Injector 

    Click here to view Mallinckrodt Coeur syringe alert.

     Mallinckrodt's Methylphenidate Hydrochloride Extended-Release Tablets, USP

    Click here for full prescribing information.  

    Mallinckrodt’s Position on Safe and Effective Use of Opioids

    Click here for Mallinckrodt’s Position on Safe and Effective Use of Opioids 

    Voluntary recall issued for Coiled Tubing

    Click here for the Coiled Tubing Recall Letter 2-10-12

    Voluntary recall issued for Disposable Magnetic Resonance Syringes/Tubing

    Click here for the Disposable MR Tubing and Syringes Recall Letter 2-10-12

  • Featured Products

    DownloadAsset.aspx?id=2040
    PENNSAID® (diclofenac sodium topical solution) 1.5% w/w

    Click Product for Boxed Warning and U.S. Full Prescribing Information Link for Additional Important Risk Information

    DownloadAsset.aspx?id=2046
    EXALGO® (hydromorphone HCl) Extended-Release Tablets, CII 8 mg

    Click Product for Boxed Warning and U.S. Full Prescribing Information Link for Additional Important Risk Information

    DownloadAsset.aspx?id=628
    Ultra-Technekow™ DTE

  • News & Press

    • Archives

    Pharmaceutical Products

    03/25/2013 8:47 AM

    Mallinckrodt Launches Additional Dosage Strengths of Generic CONCERTA® in U.S.

    36 and 54 milligram dosage strengths of ADHD treatment now available ST LOUIS--(BUSINESS WIRE)--Mar 25, 2013-- Mallinckrodt, the Pharmaceuticals business of Covidien (NYSE: COV), today announced that it launched the 36 and 54 milligram (mg) dosage strengths of ...

    Imaging Products

    02/13/2013 3:05 AM

    Mallinckrodt Medical BV will promote and distribute Rapiscan® (regadenoson) in France, Italy, Belgium, and Spain

    February 11, 2013, London – Today Rapidscan Pharma Solutions (RPS) EU Ltd announced that they have come to agreement with Mallinckrodt Medical BV (Mallinckrodt) for the exclusive right to promote and distribute Rapiscan® (regadenoson) in France, Italy, Belgium and Spain Rapiscan is a sele...

    Covidien

    05/24/2013 8:37 AM

    Covidien Board of Directors Approves Separation of Pharmaceuticals Business and Declares Dividend of Mallinckrodt Ordinary Shares

    DUBLIN--(BUSINESS WIRE)--May 24, 2013-- Covidien plc (NYSE: COV), a leading global provider of healthcare products, today announced that its board of directors has approved the separation of the Pharmaceuticals business from the rest of Covidien The separation will ...

    05/24/2013 8:38 AM

    Covidien and Mallinckrodt to Present at Deutsche Bank Conference

    MANSFIELD, Mass--(BUSINESS WIRE)--May 23, 2013-- Covidien (NYSE: COV), a leading global provider of healthcare products, will present at the Deutsche Bank 38th Annual Health Care Conference in Boston on Wednesday and Thursday, May 29 and 30, 2013 José E Almeid...



This information is intended for the use of our customers, patients and healthcare professionals in the United States only. Covidien recognizes that the Internet is a global communications medium; however, laws, regulatory requirements and medical practices for pharmaceutical products vary from country to country. The prescribing information included here may not be appropriate for use outside the United States.

  • About Us
  • Legal
  • Privacy
  • Compliance
  • Covidien
  • Patents
© 2013 Covidien. All rights reserved.